Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-02-24FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for AKYNZEO (fosnetupitant and palonosetron) from Helsinn Therapeutics (U.S.), Inc. to support i…
-
FDA approval · 2020-02-10FDA Approved: FOSAPREPITANT — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for fosaprepitant submitted by Novadoz Pharmaceuticals LLC to expand its labeling.
-
FDA approval · 2020-02-07FDA Approved: DRONABINOL — Original Application (Camber Pharmaceuticals Inc)
FDA approves Camber Pharmaceuticals' original abbreviated new drug application for dronabinol (generic). The product is indicated for chemot…
-
FDA approval · 2019-11-14FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC to expand its approved use as an antiemetic for …
-
FDA approval · 2019-11-14FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) filed by Merck Sharp & Dohme LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-11-14FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-10-30FDA Approved: METOCLOPRAMIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for metoclopramide hydrochloride from Fresenius Kabi USA, LLC.
-
FDA approval · 2019-10-29FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for palonosetron hydrochloride from Sandoz Inc, authorizing changes under the ANDA pathway.
-
FDA approval · 2019-10-21FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
The FDA approved a supplemental application for CINVANTI (aprepitant) submitted by Heron Therapeutics, Inc.
-
FDA approval · 2019-09-25FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC, resulting in updated labeling for the produ…
-
FDA approval · 2019-09-25FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Actavis Pharma, Inc.)
The FDA approved fosaprepitant as an intravenous antiemetic based on the original NDA submitted by Actavis Pharma, Inc. for prevention of ch…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Mylan Institutional LLC)
FDA approves a generic version of fosaprepitant from Mylan Institutional LLC via an Original Application (ANDA) to prevent chemotherapy-indu…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (BluePoint Laboratories)
FDA approved the original application for fosaprepitant, a generic antiemetic, to prevent chemotherapy-induced nausea and vomiting.
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Baxter Healthcare Corporation)
The FDA approved Baxter's original application for fosaprepitant dimeglumine (fosaprepitant) as an antiemetic to prevent chemotherapy-induce…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (BE Pharmaceuticals Inc.)
FDA approved the original application for Fosaprepitant filed by BE Pharmaceuticals Inc. (ANDA212309). Fosaprepitant is used to prevent chem…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves Novadoz Pharmaceuticals' Fosaprepitant via original ANDA, making a generic IV antiemetic available for prevention of chemothera…
-
FDA approval · 2019-05-24FDA Approved: METOCLOPRAMIDE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for metoclopramide hydrochloride, authorizing an updated approval for this …
-
FDA approval · 2019-02-26FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
The FDA approved a supplemental application for CINVANTI (aprepitant) from Heron Therapeutics, expanding its labeling/indication.
-
FDA approval · 2018-11-06FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Eugia US LLC)
The FDA approved Eugia US LLC's original application for palonosetron hydrochloride (generic) to prevent chemotherapy- and postoperative-ind…
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's original application for Palonosetron, a generic antiemetic, for the prevention of chemotherapy- and …
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON — Original Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA, LLC's original application for Palonosetron, a 5-HT3 receptor antagonist used to prevent chemotherapy-i…
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Mylan Institutional LLC)
FDA approved a generic palonosetron hydrochloride product from Mylan Institutional LLC through an original ANDA, intended to prevent postope…
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Sagent Pharmaceuticals)
FDA approved Palonosetron hydrochloride as a generic product through an Original Application filed by Sagent Pharmaceuticals.
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a generic palonosetron hydrochloride product to prevent chemotherapy- and surgery-induc…